- Conditions
- Amyloidosis
- Interventions
- Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 16
- States / cities
- Duarte, California • New Haven, Connecticut • Tampa, Florida + 12 more
Clinical trials in Atlanta, Georgia
This page shows live ClinicalTrials.gov search results for Atlanta, Georgia, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Institutions in Atlanta
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma, Recurrent Skin Acantholytic Squamous Cell Carcinoma, Recurrent Skin Clear Cell Squamous Cell Carcinoma, Recurrent Skin Lymphoepithelial Carcinoma, Recurrent Skin Spindle Cell Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Resectable Eyelid Squamous Cell Carcinoma, Resectable Skin Acantholytic Squamous Cell Carcinoma, Resectable Skin Clear Cell Squamous Cell Carcinoma, Resectable Skin Lymphoepithelial Carcinoma, Resectable Skin Spindle Cell Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Skin Acantholytic Squamous Cell Carcinoma, Skin Clear Cell Squamous Cell Carcinoma, Skin Lymphoepithelial Carcinoma, Skin Spindle Cell Squamous Cell Carcinoma, Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
- Interventions
- Biospecimen Collection, Cemiplimab, Computed Tomography, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Surgical Procedure
- Procedure · Biological · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 196
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 147 more
- Conditions
- Ovarian Cancer, Non-small Cell Lung Cancer
- Interventions
- TUB-040, Bevacizumab
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 10 more
- Conditions
- Cutaneous Sarcoidosis
- Interventions
- Oral Brepocitinib, Oral Placebo
- Drug
- Lead sponsor
- Priovant Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more
- Conditions
- Chronic Subdural Hematoma
- Interventions
- Experimental: Interventional Cohort: TRUFILL n-Butyl Cyanoacrylate (n-BCA) Liquid Embolic System, Standard of Care Surgery, Experimental: Interventional Cohort: TRUFILL n-BCA Liquid Embolic System, Standard of Care Medical Management
- Device · Other
- Lead sponsor
- Cerenovus, Part of DePuy Synthes Products, Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 376 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Walnut Creek, California + 28 more
- Conditions
- Cushing Syndrome
- Interventions
- relacorilant
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- Not listed
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Stanford, California • Torrance, California + 21 more
- Conditions
- Bipolar Depression
- Interventions
- Lumateperone, Placebo
- Drug
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 56
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 38 more
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- Pasritamig, Docetaxel, Prednisone/Prednisolone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 65
- States / cities
- Chandler, Arizona • Little Rock, Arkansas • Springdale, Arkansas + 57 more
- Conditions
- HIV -1 Infection
- Interventions
- Every 4-week long-acting injectable cabotegravir and rilpivirine
- Drug
- Lead sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 10
- States / cities
- La Jolla, California • Los Angeles, California • Aurora, Colorado + 7 more
- Conditions
- Multiple Myeloma
- Interventions
- Talquetamab, Pomalidomide, Teclistamab, Elotuzumab, Dexamethasone, Bortezomib
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 838 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 49
- States / cities
- Clovis, California • Santa Monica, California • New Haven, Connecticut + 41 more
- Conditions
- Alzheimer's Disease
- Interventions
- Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 42
- States / cities
- Chandler, Arizona • Garden Grove, California • Long Beach, California + 35 more
- Conditions
- PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
- Interventions
- Acasunlimab, Pembrolizumab, Docetaxel
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 36
- States / cities
- Tucson, Arizona • Los Angeles, California • Vallejo, California + 28 more